Talquetamab Continues To Demonstrate High Overall Response Rates in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma By Ogkologos - April 1, 2025 695 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MonumenTAL-1 study Source RELATED ARTICLESMORE FROM AUTHOR Adding Relacorilant to Nab-paclitaxel Prolongs OS in Patients with Platinum-Resistant Ovarian Cancer Quadruplet Isa-KRd Regimen Improves NGS-MRD Negativity in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Tarlatamab MOST POPULAR Mom Battling Cancer Lets 4-Yr-Old Give Her “Best Haircut Ever.” December 6, 2019 EMA Recommends Extension of Indications for Cabozantinib July 10, 2025 Cancer “Liquid Biopsy” Blood Test Gets Expanded FDA Approval November 30, 2020 Foodie Fridays: An Ode to Summer Tomatoes July 2, 2021 Load more HOT NEWS On legacy giving: “It allows me to give something more meaningful... Exploring Coping Resources to Help with Physical, Practical, and Emotional Challenges... Cancer in My Community: Working Toward Early Diagnosis for Children With... Breast Cancer Survivor Driven from Her Home by Noxious Gases from...
